Grifols, S.A. Sponsored ADR Class B

GRFS

$18.51

-12.03% (1 year change)

Avg closing price

Price range

Market Cap

$4.78 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$1.52 Billion

Total revenue in the last quarter.

Net Income

$35.1 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$0.9

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.2219 (1.2%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

20.57x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$153 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

24,016

The number of full time employees.

Revenue & Earnings

Balance Sheet

Grifols, S.A. Sponsored ADR Class B

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

News

Plasma Derived Drugs Market Analysis, Size and Forecast by 2026|Grifols, S.A., Octapharma

Plasma Derived Drugs Market Analysis, Size and Forecast by 2026|Grifols, S.A., Octapharma

LOS ANGELES, United States: The report titled Global Plasma Derived Drugs Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It off...

OpenPR OpenPR, 9 days ago
Intravenous Immunoglobulin (IVIg) Market Foreseen to Draw a Promising Growth of $10.8 Billion by 2025 | Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, CNBG

Intravenous Immunoglobulin (IVIg) Market Foreseen to Draw a Promising Growth of $10.8 Billion by 2025 | Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, CNBG

Global Intravenous Immunoglobulin (IVIg) Market Synopsis: The Intravenous Immunoglobulin (IVIg) Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the p...

OpenPR OpenPR, 26 days ago
Worldwide Therapeutic Drug Monitoring Industry to 2025 - Players Include Biomerieux, Theradiag & Grifols Among Others - ResearchAndMarkets.com

Worldwide Therapeutic Drug Monitoring Industry to 2025 - Players Include Biomerieux, Theradiag & Grifols Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibioti...

Business Wire Business Wire, about 1 month ago